For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials
Posted on: Wednesday, 8 July 2009, 08:00 CDT
The new Physician & Payer Forum report entitled Vytorin One Year On: How Will Prescriber Attitudes and Payer Hurdles Influence the Markets for Dyslipidemia? finds that the share of patients prescribed Vytorin and Zetia by surveyed PCPs in primary prevention has declined by three and one percentage point respectively since the conclusion of the ENHANCE and SEAS clinical trials. However, in primary prevention, the share of patients prescribed Vytorin and Zetia by cardiologists has declined by seven and four percentage points respectively during the same time period.
The report also finds that a majority of managed care organizations' (MCOs) pharmacy directors have taken action as a result of the SEAS and ENHANCE trials. The ENHANCE trial showed that Vytorin was no more effective than the less expensive generic simvastatin in reducing carotid intima-media thickness. The report's survey results indicate that Vytorin was moved to a less favorable tier in 30 percent of both commercial plans and Medicare PDPs, although these actions may have been based on some misconceptions about Vytorin's efficacy.
"Although two-thirds of surveyed pharmacy directors indicate that they are aware of the results of the ENHANCE trial, their understanding of the results appears somewhat flawed and favors simvastatin," said Decision Resources Analyst
Vytorin One Year On: How Will Prescriber Attitudes and Payer Hurdles Influence the Markets for Dyslipidemia? is based on a U.S. survey of 70 primary care physicians, 70 cardiologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 ccomfort@dresources.com emarshall@dresources.comSOURCE Decision Resources
Source: PR Newswire
Related Articles
- Beckman Coulter Signs Agreements With Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
- Walgreens Enhances Retail Pharmacy Industry's Most Comprehensive Prescription Discount Program
- Cardinal Health Expands Leader(R) Offering To Help Independent Pharmacies Strengthen Patient Relationships, Solidify Role As Local Health Care Experts
- CLSI Publishes Guideline for Verification of Comparability of Patient Results Within One Health Care System
- Metallica Resources Announces Release of Technical Report With Final Results of El Morro Feasibility Study
- Consumer Reports Survey: Patients and Doctors Disagree on Some Essential Issues
- Survey: Public Believes Decisions Concerning Treatment Should Rest With Patients and Physicians
- Essential Group, Inc. Appoints New Strategic Director of Essential Patient Recruitment(TM) Services
- Soil Change, Soil Survey, and Natural Resources Decision Making: A Blueprint for Action
- Imipenem/Cilastatin Versus Piperacillin/Tazobactam Plus Amikacin for Empirical Therapy in Febrile Neutropenic Patients: Results of the COSTINE Study*
 |
 |
User Comments (0)
RSS Feeds